ARTICLE | Financial News
Gene therapy company Audentes raises $151M
October 11, 2018 5:03 AM UTC
On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million Wednesday through the sale of 5.2 million shares at $29 in a follow-on underwritten by BofA Merrill Lynch, J.P. Morgan, Cowen and Wedbush PacGrow. The price is a 21% discount to Audentes' close of $36.70 on Tuesday, when it proposed to raise $150 million.
The company slid 19% on Wednesday before pricing the offering after market hours. It lost another $2.70 to $27.13 on Thursday...